Entrada Therapeutics
TRDA
77 hedge funds and large institutions have $369M invested in Entrada Therapeutics in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 3 closing their positions.
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
24% more funds holding
Funds holding: 62 → 77 (+15)
1.3% less ownership
Funds ownership: 78.76% → 77.46% (-1.3%)
7% less capital invested
Capital invested by funds: $397M → $369M (-$27.8M)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$1.81M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$985K |
| 3 |
Morgan Stanley
New York
|
+$824K |
| 4 |
Citigroup
New York
|
+$752K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$731K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.62M |
| 3 |
7IH
72 Investment Holdings
Stamford,
Connecticut
|
-$2.6M |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$678K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$330K |
TRDA Hedge Fund Activity: Q1 2024 in Review
77 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q1 2024, worth a combined $369M — down 7% from $397M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TRDA positions and 3 closed out — a net gain of 15 holders — while 19 added to existing stakes and 23 trimmed.
The largest buyer was American Century Companies, adding an estimated $1.81M. The largest seller was Fidelity Investments, cutting an estimated $5.2M.
- 77 institutional investors held Entrada Therapeutics (TRDA) as of Q1 2024, up from 62 in Q4 2023.
- Funds reported $369M of Entrada Therapeutics stock for Q1 2024, down 7% quarter-over-quarter.
- 18 funds opened new Entrada Therapeutics positions in Q1 2024 and 3 closed out, a net change of +15 holders.
- The largest Entrada Therapeutics buyer in Q1 2024 was American Century Companies, an estimated $1.81M added.
- The largest Entrada Therapeutics seller in Q1 2024 was Fidelity Investments, an estimated $5.2M sold.
Based on aggregated 13F filings for Q1 2024.